An interdisciplinary team of authors from Canada, Austria, the U.S. and Germany has outlined how immuno-epidemiology and ...

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the ...

This episode of The Vet Blast Podcast reveal how in-home can be a benefit to professionals, clients, and patients. On this ...

The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...

We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...

In this preview of a recent episode of dvm360’s Vet Watch hosted by Christopher Lee, DVM, MPH, DACVPM, DACVM (Parasitology), ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

Recent research has opened the debate on whether chemical imbalances cause depression, anxiety, and other conditions ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) ...